Renal Dosing Adjustments for Commonly Used Veterinary Antimicrobials

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Antimicrobial dose adjustments in renally impaired dogs and cats hinge on the drug's elimination pathway (fraction excreted unchanged), therapeutic index, and pharmacodynamic kill characteristics (concentration-dependent vs. time-dependent). Drugs with >50% renal excretion necessitate adjustment, with narrow-index drugs like aminoglycosides and flucytosine requiring rigorous modification.
• For concentration-dependent antimicrobials (e.g., aminoglycosides, fluoroquinolones), extending the dosing interval is preferred to maintain high peak concentrations while allowing for drug elimination, thereby preserving efficacy and reducing accumulation. This strategy is supported by pharmacodynamic studies demonstrating efficacy with once-daily dosing in impaired renal function.
• Time-dependent antimicrobials (e.g., beta-lactams, carbapenems) are best managed with dose reduction while maintaining the standard interval, as their efficacy correlates with the duration of drug concentration above the minimum inhibitory concentration (MIC). This approach ensures continuous coverage time while limiting peak drug accumulation.
• Estimating renal function via serum creatinine is imperfect; it rises late and is influenced by muscle mass and hydration. Acute kidney injury (AKI) requires serial monitoring due to unstable clearance, whereas chronic kidney disease (CKD) can be staged using IRIS criteria (creatinine, urine protein-to-creatinine ratio, blood pressure) for more predictable dose adjustments.
• Renal replacement therapies (hemodialysis, CRRT) significantly alter drug clearance, with hydrophilic, low molecular weight drugs being removed more readily. Dosing must account for extracorporeal clearance, often requiring dose supplementation after dialysis sessions or interval shortening during continuous therapy.
• Monitoring is critical and includes serial serum creatinine, urine output, body weight, and clinical signs of toxicity (e.g., neurologic signs with beta-lactams/metronidazole). Therapeutic drug monitoring (e.g., aminoglycoside trough concentrations) is essential for drugs with narrow therapeutic indices where assays are available.

Antimicrobial dosing in dogs and cats with renal impairment requires a structured approach that balances therapeutic efficacy against the risk of drug accumulation and toxicity. Many antimicrobials are eliminated predominantly by renal excretion, and reduced glomerular filtration alters their pharmacokinetic profiles in predictable but patient-specific ways. This article provides a practical framework for adjusting antimicrobial doses in small animal patients with acute kidney injury, chronic kidney disease, or those receiving renal replacement therapy. It is written for practicing veterinarians who need clinically applicable decision criteria instead of exhaustive pharmacokinetic derivations.

The central clinical question is straightforward: for a given antimicrobial, should the dose be reduced, the interval extended, or both? The answer depends on the drug's elimination pathway, therapeutic index, pharmacodynamic target, and the severity of renal dysfunction. This article covers the physiologic basis for renal dose adjustment, a classification system for renal impairment severity, drug-specific considerations for commonly used antimicrobial classes, and monitoring parameters that guide therapy. Where the evidence base is limited, particularly for veterinary-specific dosing recommendations, the text identifies the gap and directs the reader to appropriate reference sources.

At a Glance

Physiologic Basis for Renal Dose Adjustment

Renal excretion of antimicrobials occurs through glomerular filtration, tubular secretion, and tubular reabsorption. Glomerular filtration is the dominant mechanism for most hydrophilic antimicrobials, including beta-lactams, aminoglycosides, fluoroquinolones, and carbapenems. As nephron mass declines, the filtered load of drug falls proportionally, and the elimination half-life extends. For drugs with a wide therapeutic index, this prolongation may be clinically irrelevant. For drugs with concentration-dependent toxicity, it creates a direct risk of adverse effects.

The relationship between renal function and drug clearance is not linear across all drugs. Some antimicrobials undergo active tubular secretion, which can partially compensate for reduced filtration until dysfunction is advanced. Others are metabolized hepatically before renal excretion, making the kidney a secondary instead of primary elimination route. The fraction of drug excreted unchanged in urine is the single most useful pharmacokinetic parameter for deciding whether adjustment is necessary. This value is reported in veterinary pharmacology references and should be checked before prescribing any antimicrobial to a renally impaired patient.

Estimating Renal Function in Clinical Practice

Serum creatinine concentration remains the most accessible marker of glomerular filtration in dogs and cats, but it is an imperfect surrogate. Creatinine is influenced by muscle mass, age, and hydration status, and it rises only after filtration has already declined substantially. In acute kidney injury, serial measurements are essential because a single value may reflect a lagging equilibrium. In chronic kidney disease, the International Renal Interest Society (IRIS) staging system provides a standardized framework based on fasting serum creatinine, urine protein-to-creatinine ratio, and systolic blood pressure. IRIS stages guide both therapeutic decisions and prognostic discussions, and they offer a practical severity classification for antimicrobial dose adjustment.

Pharmacodynamic Principles Guiding Adjustment Strategy

The strategy for dose adjustment depends on whether the antimicrobial exhibits concentration-dependent or time-dependent killing. Aminoglycosides and fluoroquinolones kill most effectively when peak concentrations are high relative to the minimum inhibitory concentration (MIC). For these drugs, extending the dosing interval preserves the peak-to-MIC ratio while allowing more time for drug elimination. This approach was supported by early pharmacodynamic work with amikacin, where once-daily dosing in animals with impaired renal function produced efficacy similar to or greater than more frequent regimens while reducing accumulation Craig and colleagues' pharmacodynamic studies of amikacin.

Beta-lactams, by contrast, exhibit time-dependent killing. Their efficacy correlates with the duration that free drug concentrations remain above the MIC. Dose reduction, instead of interval extension, is the preferred adjustment for renally cleared beta-lactams because it maintains coverage time while limiting peak accumulation. Carbapenems follow the same logic. Meropenem pharmacokinetics in dogs receiving intermittent hemodialysis demonstrate that dialysis clearance contributes meaningfully to total drug elimination, and dosing must account for both residual renal function and extracorporeal clearance pharmacokinetic study of meropenem in beagle dogs on intermittent hemodialysis.

Renal Replacement Therapy and Antimicrobial Clearance

Dogs and cats undergoing intermittent hemodialysis or continuous renal replacement therapy present a special dosing challenge. The extracorporeal circuit removes drug in addition to whatever residual native clearance remains, and the relative contribution of each varies with the drug's protein binding, molecular weight, and volume of distribution. Highly protein-bound drugs are cleared less efficiently by dialysis, whereas low molecular weight, hydrophilic drugs are removed readily. In vitro work with the ADVanced Organ Support hemodialysis system demonstrated that low protein-bound antimicrobials such as meropenem and piperacillin are cleared at rates approaching 3 L/h, while highly protein-bound agents are removed far less efficiently in vitro elimination of antimicrobials during ADVanced Organ Support hemodialysis.

For patients on intermittent hemodialysis, a common strategy is to administer the antimicrobial dose after the dialysis session to avoid intra-dialytic drug loss. For continuous renal replacement therapy, maintenance doses are typically adjusted upward or the interval shortened to compensate for continuous extracorporeal clearance. Published veterinary data on antimicrobial dosing during renal replacement therapy are sparse, and clinicians should consult current pharmacokinetic literature and, where possible, therapeutic drug monitoring.

Practical Dose Adjustment Framework

Stepwise Approach to Renal Dose Modification

The clinical decision to adjust an antimicrobial dose in a dog or cat with renal impairment follows a consistent sequence. First, confirm the diagnosis of renal disease and stage its severity using the International Renal Interest Society (IRIS) staging system, which relies on fasting plasma creatinine concentration and, where available, symmetric dimethylarginine (SDMA). Second, determine whether the infection is acute or chronic, life-threatening or non-life-threatening, and whether the chosen antimicrobial is renally eliminated. Third, calculate the adjustment using the patient's estimated glomerular filtration rate (GFR) or a validated surrogate. Fourth, decide whether to extend the dosing interval, reduce the dose, or both. Fifth, plan therapeutic drug monitoring where the drug has a narrow therapeutic index and assays are available.

The adjustment strategy depends on the drug's pharmacodynamic kill characteriztic. Concentration-dependent antimicrobials such as aminoglycosides and fluoroquinolones are best adjusted by extending the dosing interval while preserving the peak concentration. Time-dependent antimicrobials such as beta-lactams are best adjusted by reducing the dose while preserving the dosing interval, because efficacy correlates with the duration that free drug concentration exceeds the minimum inhibitory concentration (MIC). This distinction is not theoretical. Amikacin demonstrates concentration-dependent killing and a prolonged postantibiotic effect, and studies in mice with impaired renal function showed that once-daily dosing produced efficacy similar to or greater than more frequent regimens, with activity correlating best with area under the curve and peak serum concentration Craig et al., pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. Extending the interval for aminoglycosides in renal impairment therefore preserves efficacy while reducing accumulation.

Interval Extension Versus Dose Reduction

Interval extension is the preferred method for drugs with a long half-life, concentration-dependent killing, or a narrow therapeutic index. It is simpler to implement because the target peak concentration is preserved. The new interval is approximated by multiplying the normal interval by the ratio of the patient's estimated GFR to a normal GFR, or by using published adjustment tables. Dose reduction is preferred for time-dependent drugs where maintaining the steady-state concentration matters more than the peak. The reduced dose is approximated by multiplying the normal dose by the ratio of the patient's estimated GFR to normal GFR, or by using published tables.

A hybrid approach is sometimes appropriate. For a severely azotemic patient receiving a beta-lactam, both a modest dose reduction and a modest interval extension may be used to avoid both toxicity from accumulation and subtherapeutic trough concentrations. The clinician should choose one primary adjustment method and document the reasoning. Switching between methods mid-course without re-evaluation invites error.

Antimicrobial Classes and Adjustment Patterns

The table above is a decision aid, not a substitute for current formulary reference. The clinician must consult the current label and a contemporary veterinary formulary before prescribing, because approved doses and adjustment recommendations change FDA Center for Veterinary Medicine animal drug information.

Step-by-Step Calculation Example

Consider a 12 kg dog with chronic kidney disease, IRIS stage 3, plasma creatinine 4.2 mg/dL, and a confirmed Pseudomonas urinary tract infection. The chosen antimicrobial is meropenem, a time-dependent carbapenem with predominantly renal elimination. The normal dose for a dog with normal renal function is 24 mg/kg intravenously every 8 hours, based on the labeled dose. The estimated GFR in this dog is approximately 30% of normal, estimated from the IRIS stage and the inverse relationship between creatinine and GFR.

Step 1. Confirm the drug is renally eliminated. Meropenem is cleared primarily by renal mechanisms, and its half-life is prolonged in renal failure. Step 2. Choose the adjustment method. Because meropenem is time-dependent, dose reduction is preferred. Step 3. Calculate the adjustment factor. The ratio of estimated GFR to normal GFR is 0.3. Step 4. Apply the factor to the dose. The adjusted dose is 24 mg/kg multiplied by 0.3, which equals 7.2 mg/kg. Step 5. Decide whether to also extend the interval. In severe impairment, a modest interval extension to every 12 hours may be appropriate to avoid accumulation. Step 6. Document the calculation in the medical record, including the estimated GFR, the adjustment factor, the calculated dose, and the monitoring plan.

This calculation is an approximation. The clinician should verify the result against a published adjustment table and consult the current formulary. Where therapeutic drug monitoring is available, measure a trough concentration before the third adjusted dose and adjust further if the trough exceeds the target.

Monitoring Parameters and Their Interpretation

Monitoring serves two purposes: detecting drug accumulation and detecting worsening renal function. Plasma creatinine and SDMA should be measured at baseline and repeated at intervals appropriate to the drug and the severity of renal disease. For a stable chronic kidney disease patient on a renally adjusted beta-lactam, rechecking every 3 to 7 days is reasonable. For an acutely azotemic patient on an aminoglycoside, daily monitoring is required.

Urine output and body weight are sensitive indicators of volume status and renal perfusion. A declining urine output in a patient receiving a renally eliminated drug should prompt immediate reassessment of the dose. Urine sediment examination detects crystalluria in patients receiving sulfonamides and casts in patients with tubular injury. Neurologic examination is essential for beta-lactams and metronidazole, because accumulation causes neurotoxicity that may present as lethargy, tremors, or seizures before biochemical changes are apparent.

Renal Replacement Therapy and Dose Supplementation

Intermittent hemodialysis removes antimicrobials to a variable degree, and the dose must be supplemented after each session. Meropenem is significantly cleared by hemodialysis in dogs. In a pharmacokinetic study of healthy beagle dogs receiving intermittent hemodialysis, dialysis clearance was 71.1 mL/h/kg, the extraction ratio was 0.455, and 21% of the administered drug was recovered in the dialysate Byun et al., pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis. The half-life decreased during dialysis compared with the interdialytic period. A practical approach is to administer the full normal dose immediately after dialysis and the reduced dose at the next scheduled interval, then re-evaluate.

Continuous renal replacement therapy and novel dialysis systems also remove antimicrobials. An in vitro study of the ADVanced Organ Support system, which uses albumin-enriched dialysate, demonstrated significant removal of both protein-bound and unbound antimicrobials, including meropenem, piperacillin, and fluconazole König et al., in vitro elimination of antimicrobials during ADVanced Organ Support hemodialysis. The clinical implication is that dose adjustments are required during and after such therapy, and the prescriber should assume that standard renal failure dose reductions are insufficient during active dialysis.

Species Differences and Practical Limitations

Dogs and cats differ in their metabolic handling of some antimicrobials. Enrofloxacin undergoes hepatic metabolism in dogs but relies more on renal clearance in cats. Dosing adjustments for enrofloxacin are therefore less critical in dogs with renal impairment than in cats. Cats also have a lower GFR per kilogram than dogs, which means that a dose adjusted for a dog of equivalent body weight may still accumulate in a cat. The clinician should apply species-specific adjustment factors where they exist and consult a feline-specific formulary.

Allometric scaling across species is imprecise for cephalosporins. A review of cephalosporin pharmacokinetics in food-producing and companion animals found that allometric scaling predicted volume of distribution and clearance well for ceftazidime, ceftiofur, cefquinome, and cefepime, but not for ceftriaxone Taverne et al., modeling concentrations of antimicrobial drugs. This finding cautions against extrapolating dose adjustments from one species to another without species-specific pharmacokinetic data.

The evidence base for renal dose adjustment in veterinary patients is limited. Most adjustment recommendations are extrapolated from human medicine or from single-dose pharmacokinetic studies in healthy animals. The clinician should acknowledge this uncertainty, document the basis for the chosen adjustment, and monitor the patient closely. When in doubt, consult the current veterinary formulary and the MSD Veterinary Manual for species-specific guidance, and apply the principles of judicious antimicrobial use endorsed by the AVMA antimicrobial stewardship resources.

Recognized Complications and Early Detection

The most consequential failure in renal dose adjustment is not the dose itself but the absence of a monitoring loop. A patient with stable azotaemia can develop progressive injury, dynamic clearance, or drug accumulation that outpaces the initial plan. Early detection depends on scheduled reassessment, not on a single adjustment event.

Acute kidney injury in a patient already receiving an adjusted regimen presents a distinct problem. The clearance estimate used for the original calculation is obsolete within hours. Detect this by repeating the serum creatinine measurement at 24 to 48 hours after initiation, then again at the midpoint of the expected dosing interval. A rising creatinine with a stable or falling urine output should trigger re-estimation and further dose modification.

Drug accumulation without worsening azotaemia is harder to detect. Aminoglycosides and flucytosine accumulate in ways that serum creatinine may not reflect promptly. For aminoglycosides, a pre-dose trough concentration measured after the third or fourth dose provides the earliest practical signal. For other agents, clinical signs such as prolonged sedation with a beta-lactam, or new gastrointestinal signs with a macrolide, should prompt a measured or estimated clearance reassessment instead of empirical dose reduction.

Hypotension during hospitalization reduces renal perfusion and drug clearance independently of structural renal disease. Any patient receiving a renally cleared antimicrobial who develops hypotension, dehydration, or receives a nephrotoxic concurrent drug should have the dosing interval re-examined. The common practice of extending an interval and then forgetting the patient is on the extended interval is a recognized source of underdosing once renal function recovers.

Common Errors and Corrective Actions

Less experienced clinicians frequently default to interval extension for every renally cleared drug. Interval extension suits concentration-dependent agents such as aminoglycosides and fluoroquinolones, where a high peak relative to the minimum inhibitory concentration drives efficacy. It suits time-dependent agents less well, because prolonged intervals can leave the free drug concentration below the minimum inhibitory concentration for a substantial portion of the interval. For beta-lactams, dose reduction with a modest interval extension, or a reduced dose at the standard interval, is often more pharmacodynamically sound. The pharmacodynamic distinction is covered in the earlier section on adjustment strategy.

A second error is treating the estimated glomerular filtration rate as a fixed number. The estimate is a snapshot. In a cat with urethral obstruction that has been decompressed, clearance can improve substantially within 48 hours. Dosing to the admission creatinine without rechecking will underdose. Conversely, a dog with leptospirosis may worsen despite supportive care, and the original adjustment will overdose. The corrective action is a scheduled recheck, not a single calculation.

A third error is ignoring protein binding when interpreting drug behavior. Highly protein-bound drugs such as ceftriaxone and cefovecin have limited glomerular filtration of the active unbound fraction, and their clearance is less dependent on renal function than their total plasma clearance suggests. Applying a standard renal adjustment formula to a highly protein-bound drug without considering the unbound fraction can lead to unnecessary dose reduction. The relationship between protein binding and renal clearance is documented for cephalosporins across species in the comparative pharmacokinetic modeling work by Taverne and colleagues, which showed that renal mechanisms dominate excretion but that protein binding differences affect elimination half-life Taverne et al., comparative pharmacokinetics of cephalosporins and allometric scaling.

A fourth error is failing to account for extracorporeal drug removal. A patient on intermittent hemodialysis may need a supplemental dose after each session. Meropenem is measurably cleared by intermittent hemodialysis in dogs, with a substantial fraction of the administered dose recovered in the dialysate, and the half-life reduction is greater in renal failure patients than in normal patients pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis. The same principle applies to other dialysis modalities, although the magnitude of clearance differs.

Limitations of the Evidence and Areas of Expert Disagreement

The veterinary evidence base for renal dose adjustment is thin. Most recommendations are extrapolated from human pharmacokinetic studies, small veterinary studies, or first principles. The cephalosporin data illustrate the problem: allometric scaling predicts volume of distribution and clearance well for some agents but poorly for others, and published information on protein binding differences is limited Taverne et al.. Extrapolation from one species to another, or from healthy animals to those with renal disease, carries real uncertainty.

Expert opinion differs on whether to reduce the dose or extend the interval for time-dependent drugs in moderate azotaemia. Some authorities favour a reduced dose at the standard interval to maintain time above the minimum inhibitory concentration. Others favour interval extension to reduce accumulation risk. Both approaches are defensible, and the choice often depends on the severity of infection, the drug's therapeutic index, and the practicality of the regimen for the owner.

The role of newer dialysis technologies is another area of uncertainty. In vitro work with the ADVanced Organ Support system shows that both protein-bound and unbound antimicrobials are removed to a significant extent, indicating that dose adjustments are required in vitro elimination of antimicrobials during ADVanced Organ Support hemodialysis. However, in vitro clearance does not translate directly to clinical dosing recommendations, and no veterinary studies have established specific supplementation protocols for this modality.

When to Refer, Consult, or Report

Referral or specialist consultation is warranted when the patient has stage 3 or 4 chronic kidney disease with a complicating infection that requires a drug with a narrow therapeutic index, when acute kidney injury is non-azotaemic but progressive, or when the clinician is uncertain whether the infection can be treated without a nephrotoxic agent. A veterinary clinical pharmacologist or internal medicine specialist can assist with therapeutic drug monitoring interpretation and with regimens for which published veterinary data are absent.

Laboratory involvement is appropriate when therapeutic drug monitoring is available for aminoglycosides or when a drug interaction is suspected. Clinical pathology support can also help distinguish prerenal from renal azotaemia when the history is ambiguous.

Regulatory reporting obligations arise in specific circumstances. Adverse drug events involving approved animal drugs should be reported to the relevant regulatory body, and the FDA Center for Veterinary Medicine maintains reporting pathways for animal drug adverse events FDA Center for Veterinary Medicine animal drug information. Extralabel use of a drug in a manner that deviates from the approved label, including dose adjustment for renal disease, must comply with the applicable extralabel use regulations in the jurisdiction of practice. Professional stewardship guidance from the AVMA reinforces that judicious use includes appropriate dose selection and monitoring AVMA antimicrobial use and stewardship resources.

Troubleshooting Guide

Frequently Asked Questions

How do I adjust antimicrobial doses when I cannot measure serum creatinine or estimate glomerular filtration rate reliably?

When laboratory access is limited, base the adjustment on history, physical examination, and response to fluid therapy. A patient with known renal disease, poor urine concentrating ability, or a history of polyuria and polydipsia should be treated as renally impaired. Choose an antimicrobial with a wide therapeutic index or one that undergoes substantial nonrenal elimination. For drugs that require adjustment, extend the interval instead of reduce the dose, because interval extension is safer when the degree of impairment is uncertain. Recheck renal parameters as soon as laboratory access becomes available. The FDA Center for Veterinary Medicine maintains label information that can guide product selection when monitoring is limited.

What should I do when a renally impaired dog requires a carbapenem and intermittent hemodialysis is available?

Meropenem is removed substantially by intermittent hemodialysis. In healthy beagles receiving hemodialysis, dialysis clearance accounted for roughly one fifth of total systemic clearance, and the extraction ratio across the dialyzer approached 0.5, with about 21% of the administered dose recovered in dialysate. The elimination half-life decreased during hemodialysis compared with the non-dialyzed state. A practical approach is to administer the dose after the dialysis session ends, then monitor for clinical response and neurologic signs. Consultation with a veterinary nephrologist or criticalist is advisable, and current formulary references should be checked for updated guidance.

How does protein binding affect my dosing decision in a patient with hypoalbuminemia and renal failure?

Hypoalbuminemia increases the free fraction of highly protein-bound antimicrobials, which can raise both efficacy and toxicity risk. Drugs that are highly protein bound, such as daptomycin and anidulafungin, show lower clearance during renal replacement therapy than weakly bound drugs. In a patient with low albumin, the unbound drug concentration may be higher than expected for a given total concentration, so monitoring for adverse effects is more important than in a normoalbuminemic patient. For weakly bound drugs, the free fraction changes little, and standard renal adjustments apply. Measure albumin when available and factor the result into the risk assessment instead of relying on total drug concentrations alone.

Can I use allometric scaling to estimate a renal dose adjustment for an exotic or unusual species?

Allometric scaling predicts volume of distribution and clearance reasonably well for many cephalosporins across species, with strong correlations between body weight and both volume of distribution and clearance for drugs such as ceftazidime and cefepime. However, the correlation was poor for ceftriaxone, and protein binding differences introduce error. Allometric estimates should be treated as a starting point, not a final dose. Confirm the estimate against published species-specific data when available, and monitor the patient closely. The MSD Veterinary Manual provides species-specific pharmacology that can supplement allometric predictions.

What records should I keep when I adjust an antimicrobial dose for renal impairment?

Document the estimated renal function at the time of the adjustment, the drug and dose selected, the rationale for the specific adjustment strategy, and the monitoring plan. Record the patient's body weight, the estimated glomerular filtration rate or creatinine value, and the date of assessment. Note any subsequent changes in renal parameters and the clinical response to therapy. This documentation supports continuity of care and provides a defensible record if the case is reviewed. The AVMA practice resources offer guidance on medical record standards and professional accountability.

How do I explain a renal dose adjustment to a client who expects a standard dose?

Explain that the kidneys remove many antimicrobials from the body, and when kidney function is reduced, the drug can accumulate to levels that cause harm. The dose is being adjusted to keep the drug concentration in the effective range while avoiding toxicity. Use a simple analogy such as a medication being cleared by a filter that is working more slowly than usual. Emphasize that the adjustment is not a sign that the infection is less serious, and that the same antimicrobial effect is expected. Reassure the client that monitoring will include blood tests to confirm the dose remains appropriate as kidney function changes.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.. 1991.
• A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.. 2010.
• <i>In vitro</i> elimination of antimicrobials during ADVanced Organ Support hemodialysis.. 2024.
• In vivo evaluation of temperature-responsive antimicrobial-loaded PNIPAAm hydrogels for prevention of surgical site infection.. 2022.
• Modeling concentrations of antimicrobial drugs: comparative pharmacokinetics of cephalosporin antimicrobials and accuracy of allometric scaling in food-producing and companion animals.. 2016.
• Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.. 2016.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Antimicrobial Stewardship in Food Animals: Principles and Practical Application
• Antimicrobial Stewardship in Equine Practice: Challenges and Solutions
• Antimicrobial Stewardship in Food Animals: Withdrawal Times and Residue Avoidance
• Antimicrobial Stewardship in Respiratory Infections of Dogs and Cats
• Antimicrobial Stewardship in Small Animal Practice: Implementing a Program

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.